Monopar Therapeutics Inc. Share Price
MNPRMonopar Therapeutics Inc. Stock Performance
Open $56.44 | Prev. Close $55.33 | Circuit Range N/A |
Day Range $56.44 - $62.58 | Year Range $28.40 - $103.77 | Volume 12,132 |
Average Traded $59.71 |
Monopar Therapeutics Inc. Share Price Chart
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-May-26 | $56.44 | $62.55 | +0.00% |
20-May-26 | $56.44 | $62.55 | +10.91% |
18-May-26 | $58.45 | $56.40 | -5.06% |
15-May-26 | $60.73 | $59.40 | -2.96% |
14-May-26 | $59.13 | $61.21 | +2.22% |
13-May-26 | $58.53 | $59.88 | -2.20% |
12-May-26 | $64.55 | $61.23 | -6.64% |